0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > DLK1

DLK1

Brief Information

Name:Coronavirus spike glycoprotein
Target Synonym:Spike glycoprotein,E2,Peplomer protein,S,SARS-CoV-2 S protein
Number of Launched Drugs:9
Number of Drugs in Clinical Trials:68
Lastest Research Phase:Approved

Product ListCompare or Buy

Nach Produktstatus:
Nach Produktkategorie :
Nach Markierungen:
Nach Konjugaten:
Kat. Nr. Arten Produktbeschreibung Struktur Reinheit Merkmal
DK1-C52H7 Cynomolgus Cynomolgus DLK1 / FA1 Protein, His Tag
DK1-C52H7-structure
DK1-C52H7-sds
DK1-H52H3 Human Human DLK1 / FA1 Protein, His Tag (MALS verified)
DK1-H52H3-structure
DK1-H52H3-sds
ACRO Quality

Part of Bioactivity data

DK1-H52H3-ELISA
 DLK1 ELISA

Immobilized Human DLK1, His Tag (Cat. No. DK1-H52H3) at 1 μg/mL (100 μL/well) can bind anti DLK-1 antibody with a linear range of 0.078-5 μg/mL (QC tested).

DK1-H52H3-MALS-HPLC
DLK1 MALS images

The purity of Human DLK1, His Tag (Cat. No. DK1-H52H3) is more than 90% and the molecular weight of this protein is around 34-51 kDa verified by SEC-MALS.

Synonym Name

DLK1,FA1,Protein delta homolog 1,Pg2,Fetal antigen 1

Background

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Recombinant novel coronavirus vaccine (adenovirus type 5 vector) (CanSinoBio) Approved Tianjin Cansino Biotechnology Inc, Chinese Academy Of Military Medical Sciences 克威莎, Convidecia, Convidecia Air Mainland China Coronavirus Disease 2019 (COVID-19) Tianjin Cansino Biotechnology Inc 2021-02-25 Coronavirus Disease 2019 (COVID-19) Details
Amubarvimab/Romlusevimab BRII-196/BRII-198 Approved Tsinghua University, Shenzhen Third People'S Hospital, Brii Biosciences (Beijing) Co Ltd Mainland China Coronavirus Disease 2019 (COVID-19) Tengsheng Huachuang Medical Technology (Beijing) Co Ltd 2021-12-08 Coronavirus Disease 2019 (COVID-19); Coronavirus Infections Details
Gam-COVID-Vac Approved Gamaleya Research Institute Of Epidemiology And Microbiology, Gamaleya Research Institute Of Epidemiology And Microbiology, Health Ministry Of The Russian Federation Sputnik V Russian Federation Coronavirus Disease 2019 (COVID-19) Gamaleya Research Institute Of Epidemiology And Microbiology 2020-08-11 Coronavirus Disease 2019 (COVID-19); Coronavirus Infections Details
Recombinant SARS-CoV-2 vaccine (CHO Cell) (Zhifei Longcom Biopharmaceutical) ZF2001 Approved Anhui Zhifei Longcom Biopharmaceutical Co Ltd, Institute Of Microbiology Of Chinese Academy Of Sciences 智克威得 Uzbekistan Coronavirus Disease 2019 (COVID-19) Anhui Zhifei Longcom Biopharmaceutical Co Ltd 2021-03-01 Coronavirus Disease 2019 (COVID-19); Coronavirus Infections Details
Regdanvimab CT-P59 Approved Celltrion Inc Regkirona South Korea Coronavirus Disease 2019 (COVID-19) Celltrion Inc 2021-09-18 Coronavirus Disease 2019 (COVID-19) Details
Tozinameran BNT162b2; PF-07302048; BNT-161b1; BNT162; Bnt-162b2; BNT162b2SA; BNT-162b5 Approved Pfizer Inc, Biontech Se 復必泰, Comirnaty, 复必泰 United Kingdom Coronavirus Disease 2019 (COVID-19) Biontech Se 2020-12-02 Infections; Anaphylaxis; Coronavirus Disease 2019 (COVID-19); Neoplasms; Severe Acute Respiratory Syndrome; Coronavirus Infections; Coronaviridae Infections Details
Tixagevimab/Cilgavimab AZD-7442; AZD7442 Approved Vanderbilt University Medical Center Evusheld, 恩适得 United Kingdom Coronavirus Disease 2019 (COVID-19) Astrazeneca Uk Ltd 2022-03-16 Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Coronaviridae Infections; Leukemia, Lymphocytic, Chronic, B-Cell Details
Casirivimab/imdevimab REGN-10933+REGN-10987; RG-6413+RG6412; REGEN-COV-2; REGN-COV2; REGN-COV-2; REGEN-COV Approved Regeneron Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd ロナプリーブ, REGEN-COV, RONAPREVE Japan Coronavirus Disease 2019 (COVID-19) Chugai Pharmaceutical Co Ltd 2021-07-19 Coronavirus Disease 2019 (COVID-19); Rejection of organ transplantation; Coronavirus Infections; Chronic Disease Details
Sotrovimab VIR-7831; GSK-4182136 Approved Vir Biotechnology Inc Xevudy Australia Coronavirus Disease 2019 (COVID-19) Vir Biotechnology Inc 2021-08-23 Hematologic Neoplasms; Solid tumours; Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections; Lymphoma Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Ogalvibart/Crexavibart BMS-986414 + BMS-986413 Phase 3 Clinical The Rockefeller University, Bristol Myers Squibb Srlcompany Coronavirus Disease 2019 (COVID-19); Coronavirus Infections Details
IBIO123 IBIO-123 Phase 2 Clinical Immune Biosolutions Inc Coronavirus Disease 2019 (COVID-19) Details
SI-F019 SI-F019; F-019; SZ-F019 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Details
Reluscovtogene ralaplasmid INO-4800; INO4800; PGX-9501 Phase 2 Clinical Inovio Pharmaceuticals Inc Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Hepatitis B Details
Recombinant SARS-CoV-2 Vaccine(variant)(Shanghai Zerun) Phase 2 Clinical Shanghai Zerun Biotechnology Co Ltd Coronavirus Disease 2019 (COVID-19) Details
GSK-4362620A GSK-4362620A Phase 3 Clinical Medicago Inc, Gsk Vaccines Gmbh Coronavirus Disease 2019 (COVID-19) Details
Ad5-triCoV/Mac Ad5-triCoV/Mac Phase 1 Clinical Canadian Institutes Of Health Research (Cihr), Mcmaster University Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections Details
ABBV-47D11 HBM9022; ABBV-47D11; HBM-9022; 47D11 Phase 1 Clinical Abbvie Inc Coronavirus Disease 2019 (COVID-19) Details
COR-101 STE90-C11 Phase 2 Clinical Corat Therapeutics Gmbh Coronavirus Disease 2019 (COVID-19) Details
Simaravibart MAD-0004J08 Phase 3 Clinical Fondazione Toscana Life Sciences Coronavirus Disease 2019 (COVID-19) Details
VYD222 VYD222; VYD-222 Phase 3 Clinical Invivyd Inc Coronavirus Disease 2019 (COVID-19) Details
Riltozinameran Phase 3 Clinical Biontech Se, Pfizer Inc Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections Details
ADM-03820 Phase 1 Clinical Ology Bioservices Inc Coronavirus Disease 2019 (COVID-19); Severe Acute Respiratory Syndrome Details
ChAd-triCoV ChAd-triCoV Phase 1 Clinical Canadian Institutes Of Health Research (Cihr), Mcmaster University Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections Details
IMM-BCP-01 IMM-BCP-01 Phase 1 Clinical Immunome Inc Coronavirus Disease 2019 (COVID-19) Details
STI-2099 STI-2099 Phase 2 Clinical Sorrento Therapeutics Inc Coronavirus Disease 2019 (COVID-19) Details
Romlusevimab BRII198; BRII-198 Phase 3 Clinical Brii Biosciences (Beijing) Co Ltd Coronavirus Disease 2019 (COVID-19) Details
Ensovibep MP-0420 Phase 3 Clinical Molecular Partners Ag Coronavirus Disease 2019 (COVID-19) Details
Etesevimab LY-3832479; LY-CoV016; JS-016 Phase 2 Clinical Institute Of Microbiology Of Chinese Academy Of Sciences, Shanghai Junshi Biosciences Co Ltd Coronavirus Disease 2019 (COVID-19); Severe Acute Respiratory Syndrome Details
DXP-593 BGB DXP593; DXP-593 Phase 2 Clinical Singlomics Biopharmaceuticals Co Ltd Coronavirus Disease 2019 (COVID-19) Details
GRT-R-912 GRT-R912; GRT-R-912 Phase 1 Clinical Gritstone Bio Inc Coronavirus Disease 2019 (COVID-19) Details
GRT-R-914 GRT-R914; GRT-R-914 Phase 1 Clinical Gritstone Bio Inc Coronavirus Disease 2019 (COVID-19) Details
AVACC-10 AVACC-10 Phase 1 Clinical Intravacc Coronavirus Disease 2019 (COVID-19) Details
REGN17092 REGN-17092; REGN17092 Regeneron Pharmaceuticals Inc Details
IN-006 IN-006 Phase 1 Clinical Celltrion Inc Coronavirus Disease 2019 (COVID-19) Details
Crexavibart C144-LS; C144LS; BMS-986413 Phase 1 Clinical The Rockefeller University, Bristol Myers Squibb Srlcompany Coronavirus Disease 2019 (COVID-19) Details
Ogalvibart BMS-986414 Phase 1 Clinical Bristol Myers Squibb Srlcompany, The Rockefeller University Coronavirus Disease 2019 (COVID-19) Details
GLS-5310 GLS-5310 Phase 2 Clinical Geneone Life Science Inc Coronavirus Disease 2019 (COVID-19) Details
BAT-2022 BAT-2022 Phase 1 Clinical Bio-Thera Solutions Ltd Coronavirus Disease 2019 (COVID-19) Details
Enuzovimab HFB-3013; HFB30132A Phase 1 Clinical HiFiBiO Therapeutics Coronavirus Disease 2019 (COVID-19) Details
SA-55 SA55; SA-55; BD55-5514 Phase 2 Clinical Sinovac Biotech Co Ltd Coronavirus Disease 2019 (COVID-19) Details
AKS-452-X AKS-452-X; AKS-452X Phase 2 Clinical Akston Biosciences Corp Coronavirus Disease 2019 (COVID-19) Details
Sipavibart AZD-3152; AZD3152 Phase 2 Clinical Astrazeneca Plc Coronavirus Disease 2019 (COVID-19) Details
HLX-71 HLX-71 Phase 1 Clinical Shanghai Henlius Biotech Inc Coronavirus Disease 2019 (COVID-19) Details
Betuvax-CoV-2 Phase 2 Clinical Human Stem Cells Institute, Russia Coronavirus Disease 2019 (COVID-19) Details
Imdevimab RG-6412 Phase 3 Clinical F. Hoffmann-La Roche Ltd Coronavirus Disease 2019 (COVID-19) Details
BGB-DXP604 DXP-604 Phase 2 Clinical Beigene Ltd, Singlomics Biopharmaceuticals Co Ltd Coronavirus Disease 2019 (COVID-19) Details
LY-CovMab LY-CovMab Phase 2 Clinical Luye Pharma Group Ltd Coronavirus Disease 2019 (COVID-19) Details
SCB-2020S SCB-2020S Phase 1 Clinical Clover Biopharmaceuticals Aus Pty Ltd Coronavirus Disease 2019 (COVID-19) Details
SARS-CoV-2 mRNA Vaccine(Argorna) RBMRNA-176 Phase 2 Clinical Argorna Pharmaceuticals Ltd Coronavirus Disease 2019 (COVID-19) Details
Bamlanivimab LY-3819253 Phase 3 Clinical AbCellera Biologics Inc, Eli Lilly And Company Coronavirus Disease 2019 (COVID-19); Coronavirus Infections Details
Equine immunoglobulin anti SARS-CoV-2 (Caja Costarricense de Seguro Social) Phase 2 Clinical Universidad De Costa Rica Coronavirus Disease 2019 (COVID-19) Details
Gorivitug REGN-15160 Phase 1 Clinical Regeneron Pharmaceuticals Inc Coronavirus Disease 2019 (COVID-19) Details
PTX-COVID19-B Phase 3 Clinical Providence Therapeutics Holdings Inc Coronavirus Disease 2019 (COVID-19) Details
HY-3000 HY-3000 Phase 2 Clinical Hybio Pharmaceutical Co Ltd Coronavirus Disease 2019 (COVID-19) Details
Amubarvimab BRII-196; BRII196 Phase 3 Clinical Brii Biosciences (Beijing) Co Ltd Coronavirus Disease 2019 (COVID-19) Details
MTx-COVAB36 MTx-COVAB36 Phase 1 Clinical Memo Therapeutics AG Coronavirus Disease 2019 (COVID-19) Details
CT-P63 CT-P-63; CT-P63 Phase 1 Clinical Celltrion Inc Coronavirus Disease 2019 (COVID-19) Details
GB-0669 GB-0669 Phase 1 Clinical Generate Biomedicines Inc Coronavirus Disease 2019 (COVID-19) Details
ABP-300 ABP-300; MW-05(Mabwell/Abpro) Phase 3 Clinical Mabwell (Shanghai) Bioscience Co Ltd, Abpro Corp Coronavirus Disease 2019 (COVID-19) Details
ChulaCov19 mRNA vaccine Phase 2 Clinical Chulalongkorn University Coronavirus Disease 2019 (COVID-19) Details
FBR-002 FBR-002 Phase 2 Clinical Fabentech Coronavirus Disease 2019 (COVID-19) Details
Casirivimab RG-6413 Phase 2 Clinical F. Hoffmann-La Roche Ltd Coronavirus Disease 2019 (COVID-19) Details
Anti-SARS-CoV-2 IgY (Stanford University) Phase 1 Clinical Stanford University Coronavirus Disease 2019 (COVID-19) Details
MW-33 MW-33; 9MW3311; 9-MW3311; 9MW-3311; 9-MW-3311 Phase 2 Clinical Mabwell (Shanghai) Bioscience Co Ltd Coronavirus Disease 2019 (COVID-19) Details
CG-SpikeDown Phase 1 Clinical Caregen Co Ltd Details
B/HPIV3/S-6P B/HPIV-3/S-6-P Phase 1 Clinical National Institutes Of Health Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections Details
JMB-2002 JMB-2002 Phase 1 Clinical Jiangxi Jemincare Group Co Ltd Coronavirus Disease 2019 (COVID-19) Details
JS-026 JS-026 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Coronavirus Disease 2019 (COVID-19) Details
abdavomeran BNT162b1 Phase 3 Clinical Biontech Se Respiratory Tract Infections; RNA Virus Infections; Drug-Related Side Effects and Adverse Reactions; Virus Diseases; Coronavirus Disease 2019 (COVID-19); Coronaviridae Infections Details
PA-001(PeptiDream) Phase 1 Clinical Peptidream Coronavirus Disease 2019 (COVID-19) Details
Upanovimab HB-27; SCTA-01 Phase 3 Clinical SinoCelltech Ltd Coronavirus Disease 2019 (COVID-19) Details
Bebtelovimab LY-CoV1404 monoclonal antibody; LY-3853113; LY-CoV 1404 mAb; LY-CoV1404 Phase 2 Clinical Eli Lilly And Company Coronavirus Disease 2019 (COVID-19) Details
F-61 F-61 Phase 1 Clinical Wuhan Institute Of Biological Products Co Ltd Coronavirus Disease 2019 (COVID-19) Details
Lomtegovimab BI-767551 Phase 2 Clinical University Of Cologne Coronavirus Disease 2019 (COVID-19) Details
GRT-R-918 GRT-R918; GRT-R-918 Phase 1 Clinical Gritstone Bio Inc Coronavirus Disease 2019 (COVID-19) Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Nachricht schicken